Fasudil (DrugBank: Fasudil)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 3 |
| 51 | Scleroderma | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003676-31-FR (EUCTR) | 31/12/2019 | 25/04/2018 | Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS | Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS | Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Eril® INN or Proposed INN: FASUDIL HYDROCHLORIDE Other descriptive name: FASUDIL HYDROCHLORIDE | Georg-August-Universität Göttingen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 2 | France;Germany;Switzerland | ||
| 2 | NCT03792490 (ClinicalTrials.gov) | February 20, 2019 | 28/12/2018 | Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | Amyotrophic Lateral Sclerosis | Drug: Fasudil;Drug: Placebo | University Medical Center Goettingen | NULL | Recruiting | 18 Years | N/A | All | 120 | Phase 2 | France;Germany;Switzerland |
| 3 | NCT01935518 (ClinicalTrials.gov) | September 2013 | 1/9/2013 | A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Historical Placebo Controlled Screening Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Fasudil | Peking University Third Hospital | NULL | Recruiting | 18 Years | 70 Years | Both | 10 | Phase 2 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00498615 (ClinicalTrials.gov) | April 2007 | 6/7/2007 | A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon | Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon | Raynaud;Scleroderma | Drug: Fasudil | Johns Hopkins University | NULL | Completed | 18 Years | 80 Years | All | 17 | Phase 3 | United States |